Tyrogenex, Xcovery appoint Michael Webb CEO
This article was originally published in Scrip
Executive Summary
Tyrogenex and Xcovery, two privately held companies focused on the development of next-generation targeted therapeutics for cancer and ophthalmology, have named Michael D Webb as president and CEO of both companies. The boards of both companies appointed Mr Webb, who has been CEO of four biotechnology companies as well as chair of the MassBio industry organization. Most recently, he was president and CEO of Allegro Diagnostics, a venture-backed, molecular diagnostics company focused on lung cancer that was acquired by Veracyte in 2014. Sheridan Snyder, co-founder and former president and CEO of both companies, remains chair of the Xcovery board and a director on the Tyrogenex board. Tyrogenex and Xcovery share a common scientific legacy and management team. Xcovery is developing X-396, an anaplastic lymphoma kinase inhibitor for non-small cell lung cancer entering Phase III this year. Tyrogenex is developing X-82, an orally administered, dual VEGFR/PDGFR inhibitor for angiogenesis in oncology and wet age-related macular degeneration.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.